Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15439
|
| Title: | Secular trend of anti-osteoporosis medication initiation in Taiwan between 2008 and 2018: Age matters |
| Authors: | Yang, TH;Yang, RS;Fu, SH;Wang, CY;Hwang, JS;Wu, CH |
| Contributors: | National Center for Geriatrics and Welfare Research |
| Abstract: | Objective: To examine the 11-year trend of anti-osteoporosis medication (AOM) usage and its impact on fractures in Taiwan. Methods: This study utilized a nationwide cohort from the National Health Insurance Research Database in Taiwan. Patients who started a new AOM between 2008–2018, including denosumab, zoledronate, ibandronate, alendronate, raloxifene, and risedronate were included. Patients under 50 years old, with pathological fractures, missing data, or receiving two AOMs were excluded. The subsequent fragility fractures within 3 years were estimated. Results: 336,229 patients with a mean age of 73.3 years meet the inclusion criteria, and 80% were female. The number of AOM initiators fluctuated, from 32,606 in 2008 to 36,580 in 2018. An immediate drop in AOMs prescription after the implementation of a new stricter reimbursement policy in 2011 (AOM users was 23,226 in 2011). It took 5 years, until 2017, for the annual number of AOM prescriptions to return to its 2008 level (34,190 in 2017). When compared with 2008, the number of patients who initiated AOMs increased by 37% and 23% for those aged between 60–69 and aged older than 80 years old, respectively. While the number of AOM users decreased by nearly 6% and 4% among those aged 50–59 and 70–79, respectively. Both subsequent fragility fracture rates within 3 years showed a slight increase after 2014 (from 3.42% in 2008 to 13.44% in 2014), then decreased after 2017 (12.18% in 017). Conclusion: Although the population aging fast in Taiwan, only a slight increase in the number of AOM users between 2008–2018 in Taiwan. The number of AOM users even decreased among those aged 50–59 and 70–79 years old. Fortunately, the overall fragility fracture rate decreased. Acknowledgments: Ministry of Health and Welfare for providing administrative support and the Taiwan Osteoporosis Association for financial support. |
| Date: | 2023-07-21 |
| Relation: | Aging Clinical and Experimental Research. 2023 Jul 21;35:S243. |
| Link to: | http://dx.doi.org/10.1007/s40520-023-02442-7 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1594-0667&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001058500202012 |
| Appears in Collections: | [王貞予] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001058500202012.pdf | | 68Kb | Adobe PDF | 32 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
